Anti-androgenic effects of S-40542, a novel non-steroidal selective androgen receptor modulator (SARM) for the treatment of benign prostatic hyperplasia

Prostate

Volumn 72, Issue 14, 2012, Pages 1580-1587

  Nejishima, Hiroaki ^a,b   Yamamoto, Noriko ^a   Suzuki, Mika ^a   Furuya, Kazuyuki ^a   Nagata, Naoya ^a   Yamada, Shizuo ^b  

^a KAKEN PHARMACEUTICAL CO LTD   (Japan)

^b UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

anti androgen; benign prostate hyperplasia; selective androgen receptor modulator

Indexed keywords

1 (8 NITRO 3A, 4, 5, 9B TETRAHYDRO 3H CYCLOPENTA[C]QUINOLIN 4 YL) ETHANE 1,2 DIOL; 1,2,3,4 TETRAHYDROQUINOLINE DERIVATIVE; ANDROGEN RECEPTOR; CELL NUCLEUS RECEPTOR; FLUTAMIDE; LUCIFERASE; LUTEINIZING HORMONE; S 40542; SELECTIVE ANDROGEN RECEPTOR MODULATOR; TESTOSTERONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ASSAY; DOSE RESPONSE; DRUG EFFECT; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; LEVATOR ANI MUSCLE; LUTEINIZING HORMONE BLOOD LEVEL; MALE; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RAT; RECEPTOR AFFINITY; TESTOSTERONE BLOOD LEVEL;

ANIMALS; BINDING, COMPETITIVE; CELL LINE; HUMANS; INHIBITORY CONCENTRATION 50; LUTEINIZING HORMONE; MALE; NONSTEROIDAL ANTI-ANDROGENS; ORGAN SIZE; PROSTATIC HYPERPLASIA; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANDROGEN; REGRESSION ANALYSIS; TESTOSTERONE;

EID: 84865498028     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22511     Document Type: Article

References (22)

1. Mooradian AD, Morley JE, Korenman SG,. Biological actions of androgens. Endocr Rev 1987; 8: 1-28.
2. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM,. The nuclear receptor superfamily: The second decade. Cell 1995; 83: 835-839.
3. Prescott J, Coetzee GA,. Molecular chaperones throughout the life cycle of the androgen receptor. Cancer Lett 2006; 231: 12-19. (Pubitemid 41779448)
4. Lee DK, Chang C,. Molecular communication between androgen receptor general transcription machinery. J Steroid Biochem Mol Biol 2003; 84: 41-49. (Pubitemid 36324436)
5. Heemers HV, Tindall DJ,. Androgen receptor (AR) coregulators: A diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 2007; 28: 778-808. (Pubitemid 350294296)
6. Masumori N,. Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia. Ther Clin Risk Manag 2011; 7: 227-238.
7. Chacon A, Monga M,. Medical management of benign prostatic hyperplasia. Geriatr Nephrol Urol 1999; 9: 39-48. (Pubitemid 29349232)
8. Lepor H,. Medical treatment of benign prostatic hyperplasia. Rev Urol 2011; 13: 20-33.
9. Gao W, Kim J, Dalton JT,. Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands. Pharm Res 2006; 23: 1641-1658. (Pubitemid 44200526)
10. Narayan P, Trachtenberg J, Lepor H, Debruyne FM, Tewari A, Stone N, Das S, Jimenez-Cruz JF, Shearer R, Klimberg I, Schellhammer PF, Costello AJ,. A dose-response study of the effect of flutamide on benign prostatic hyperplasia: Results of a multicenter study. Urology 1996; 47: 497-504. (Pubitemid 26165976)
11. Lõpez AM, Pena MA, Hernández R, Val F, Martín B, Riancho JA,. Fracture risk in patients with prostate cancer on androgen deprivation therapy. Osteoporos Int 2005; 16: 707-711. (Pubitemid 40897469)
12. Qoubaitary A, Swerdloff RS, Wang C,. Advances in male hormone substitution therapy. Expert Opin Pharmacother 2005; 6: 1493-1506. (Pubitemid 41131689)
13. Gao W, Kearbey JD, Nair VA, Chung K, Parlow AF, Miller DD, Dalton JT,. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5α-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: New approach for benign prostate hyperplasia. Endocrinology 2004; 145: 5420-5428. (Pubitemid 39564578)
14. Allan G, Lai MT, Sbriscia T, Linton O, Haynes-Johnson D, Bhattacharjee S, Dodds R, Fiordeliso J, Lanter J, Sui Z, Lundeen S,. A selective androgen receptor modulator that reduces prostate tumor size and prevents orchidectomy-induced bone loss in rats. J Steroid Biochem Mol Biol 2007; 103: 76-83. (Pubitemid 44821817)
15. Vajda EG, Lõpez FJ, Rix P, Hill R, Chen Y, Lee KJ, O'Brien Z, Chang WY, Meglasson MD, Lee YH,. Pharmacokinetics and pharmacodynamics of LGD-3303 [9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo-[3,2-f] quinolin-7(6H)-one], an orally available nonsteroidal-selective androgen receptor modulator. J Pharmacol Exp Ther 2009; 328: 663-670.
16. Schmidt A, Harada S, Kimmel DB, Bai C, Chen F, Rutledge SJ, Vogel RL, Scafonas A, Gentile MA, Nantermet PV, McElwee-Witmer S, Pennypacker B, Masarachia P, Sahoo SP, Kim Y, Meissner RS, Hartman GD, Duggan ME, Rodan GA, Towler DA, Ray WJ,. Identification of anabolic selective androgen receptor modulators with reduced activities in reproductive tissues and sebaceous glands. J Biol Chem 2009; 284: 36367-36376.
17. Hanada K, Furuya K, Yamamoto N, Nejishima H, Ichikawa K, Nakamura T, Miyakawa M, Amano S, Sumita Y, Oguro N,. Bone anabolic effects of S-40503, a novel nonsteroidal selective androgen receptor modulator (SARM), in rat models of osteoporosis. Biol Pharm Bull 2003; 26: 1563-1569. (Pubitemid 41699636)
18. Gao W, Dalton JT,. Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). Drug Discov Today 2007; 12: 241-248.
19. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL,. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10: 33-39. (Pubitemid 38524696)
20. Taplin ME, Balk SP,. Androgen receptor: A key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 2004; 91: 483-490.
21. Heinlein CA, Chang C,. Androgen receptor in prostate cancer. Endocr Rev 2004; 25: 276-308. (Pubitemid 38501396)
22. Narayanan R, Coss CC, Yepuru M, Kearbey JD, Miller DD, Dalton JT,. Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways. Mol Endocrinol 2008; 22: 2448-2465.